Promising diabetes therapy based on the molecular mechanism for glucose toxicity: Usefulness of SGLT2 inhibitors as well as incretin-related drugs

Current Medicinal Chemistry

Volumn 23, Issue 27, 2016, Pages 3044-3051

  Kaneto, Hideaki ^a   Obata, Atsushi ^a   Shimoda, Masashi ^a   Kimura, Tomohiko ^a   Hirukawa, Hidenori ^a   Okauchi, Seizo ^a   Matsuoka, Taka Aki ^b   Kaku, Kohei ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Glucose toxicity; Incretin; Insulin; MafA; SGLT2

Indexed keywords

ANTIDIABETIC AGENT; GLITAZONE DERIVATIVE; INCRETIN; INSULIN RECEPTOR SUBSTRATE 2; PIOGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TRANSCRIPTION FACTOR 7 LIKE 2; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; INSULIN; SODIUM GLUCOSE COTRANSPORTER 2;

CELL PROTECTION; DIABETES MELLITUS; GLUCOTOXICITY; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SYNTHESIS; MOLECULAR MECHANICS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN EXPRESSION; REVIEW; TARGET TISSUE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENETICS; METABOLISM;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; INSULIN-SECRETING CELLS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84990912990     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160627102516     Document Type: Review

References (78)

1. Rhodes, C.J. Type 2 diabetes-A matter of beta-cell life and death? Science, 2005, 307, 380-384.
2. Halban, P.A.; Polonsky, K.S.; Bowden, D.W.; Hawkins, M.A.; Ling, C.; Mather, K.J.; Powers. A.C.; Rhodes, C.J.; Sussel, L.; Weir, G.C. β-cell failure in type 2 diabetes: Postulated mechanisms and prospects for prevention and treatment. Diabetes Care, 2014, 37, 1751-1758.
3. Kaneto, H. Pancreatic α-cell glucose toxicity in type 2 diabetes mellitus. Curr. Diabetes Rev., 2015, 11, 2-6.
4. McGarry, J.D. Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes, 2002, 51, 7-18.
5. Poitout, V.; Robertson, R.P. Minireview: Secondary betacell failure in type 2 diabetes-A convergence of glucotoxicity and lipotoxicity. Endocrinology, 2002, 143, 339-342.
6. Prentki, M.; Nolan, C.J. Islet β cell failure in type 2 diabetes. J. Clin. Invest., 2006, 116, 1802-1812.
7. Kaneto, H.; Matsuoka, T. Role of pancreatic transcription factors in maintenance of mature α-cell function. Int. J. Mol. Sci., 2015, 16, 6281-6297.
8. Matsuoka, T.; Kajimoto, Y.; Watada, H.; Kaneto, H.; Kishimoto, M.; Umayahara, Y.; Fujitani, Y.; Kamada, T.; Kawamori, R.; Yamasaki, Y. Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells. J. Clin. Invest., 1997, 99, 144-150.
9. Ihara, Y.; Toyokuni, S.; Uchida, K.; Odaka, H.; Tanaka, T.; Ikeda, H.; Hiai, H.; Seino, Y.; Yamada, Y. Hyperglycemia causes oxidative stress in pancreatic α-cells of GK rats, a model of type 2 diabetes. Diabetes, 1999, 48, 927-932.
10. Maechler, P.; Jornot, L.; Wollheim, C.B. Hydrogen peroxide alters mitochondrial activation and insulin secretion in pancreatic beta cells. J. Biol. Chem., 1999, 274, 27905-27913.
11. Kaneto, H.; Kajimoto, Y.; Miyagawa, J.; Matsuoka, T.; Fujitani, Y.; Umayahara, Y.; Hanafusa, T.; Matsuzawa, Y.; Yamasaki, Y.; Hori, M. Beneficial effects of antioxidants for diabetes: Possible protection of pancreatic α-cells against glucose toxicity. Diabetes, 1999, 48, 2398-2406.
12. Kaneto, H.; Xu, G.; Song, K.H.; Suzuma, K.; Bonner-Weir, S.; Sharma, A.; Weir, G.C. Activation of the hexosamine pathway leads to deterioration of pancreatic α-cell function by provoking oxidative stress. J. Biol. Chem., 2001, 276, 31099-31104.
13. Kawamori, D.; Kajimoto, Y.; Kaneto, H.; Umayahara, Y.; Fujitani, Y.; Miyatsuka, T.; Watada, H.; Leibiger, L.B.; Yamasaki, Y.; Hori, M. Oxidative stress induces nucleocytoplasmic translocation of pancreatic transcription factor PDX-1 through activation of c-Jun N-terminal kinase. Diabetes, 2003, 52, 2896-2904.
14. Kaneto, H.; Matsuoka, T.; Nakatani, Y.; Kawamori, D.; Miyatsuka, T.; Matsuhisa, M.; Yamasaki, Y. Oxidative stress, ER stress, and the JNK pathway in type 2 diabetes. J. Mol. Med., 2005, 83, 429-439.
15. Robertson, R.P.; Harmon, J.; Tran, P.O.; Tanaka, Y.; Takahashi, H. Glucose toxicity in α-cells: Type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes, 2003, 52, 581-587.
16. Robertson, R.P. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J. Biol. Chem., 2004, 279, 42351-42354.
17. Tanaka, Y.; Gleason, C.E.; Tran, P.O.T.; Harmon, J.S.; Robertson, R.P. Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc. Natl. Acad. Sci. USA, 1999, 96, 10857-10862.
18. Tanaka, Y.; Tran, P.O.T.; Harmon, J.; Robertson, R.P. A role of glutathione peroxidase in protecting pancreatic α cells against oxidative stress in a model of glucose toxicity. Proc. Natl. Acad. Sci. USA, 2002, 99, 12363-12368.
19. Harmon, J.S.; Stein, R.; Robertson, R.P. Oxidative stressmediated, post-translational loss of MafA protein as a contributing mechanism to loss of insulin gene expression in glucotoxic beta cells. J. Biol. Chem., 2005, 280, 11107-11113.
20. Ohlsson, H.; Karlsson, K.; Edlund, T. IPF1, a homeodomain-containing-transactivator of the insulin gene. EMBO J., 1993, 12, 4251-4259.
21. Leonard, J.; Peers, B.; Johnson, T.; Ferreri, K.; Lee, S.; Montminy, M.R. Characterization of somatostatin transactivating factor-1, a novel homeobox factor that stimulates somatostatin expression in pancreatic islet cells. Mol. Endocrinol., 1993, 7, 1275-1283.
22. Miller, C.P.; McGehee, R.E.; Habener, J.F. IDX-1: A new homeodomain transcription factor expressed in rat pancreatic islets and duodenum that transactivates the somatostatin gene. EMBO J., 1994, 13, 1145-1156.
23. Jonsson, J.; Carlsson, L.; Edlund, T.; Edlund, H. Insulinpromoter-factor 1 is required for pancreas development in mice. Nature, 1994, 37, 606-609.
24. Ahlgren, U.; Jonsson, J.; Jonsson, L.; Simu, K.; Edlund, H. α-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the α-cell phenotype and maturity onset diabetes. Genes Dev., 1998, 12, 1763-1768.
25. Holland, A.M.; Hale, M.A.; Kagami, H.; Hammer, R.E.; MacDonald, R.J. Experimental control of pancreatic development and maintenance. Proc. Natl. Acad. Sci. USA, 2002, 99, 12236-12241.
26. Noguchi, H.; Kaneto, H.; Weir, G.C.; Bonner-Weir, S. PDX-1 protein containing its own Antennapedia-like protein transduction domain can transduce pancreatic duct and islet cells. Diabetes, 2003, 52, 1732-1737.
27. Kaneto, H.; Nakatani, Y.; Miyatsuka, T.; Matsuoka, T.; Matsuhisa, M.; Hori, M.; Yamasaki, Y. PDX-1/VP16 fusion protein, together with NeuroD or Ngn3, markedly induces insulin gene transcription and ameliorates glucose tolerance. Diabetes, 2005, 54, 1009-1022.
28. Miyatsuka, T.; Kaneto, H.; Shiraiwa, T.; Matsuoka, T.; Yamamoto, K.; Kato, K.; Nakamura, Y.; Akira, S.; Takeda, K.; Kajimoto, Y.; Yamasaki, Y.; Sandgren, E.P.; Kawaguchi, Y.; Wright, C.V.E.; Fujitani, Y. Persistent expression of PDX-1 causes acinar-to-duct transition through Stat3 activation. Genes Develop., 2006, 20, 1435-1440.
29. Zhou, Q.; Brown, J.; Kanarek, A.; Rajagopal, J.; Melton, D.A. In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature, 2008, 455, 627-32.
30. Miyashita, K.; Miyatsuka, T.; Matsuoka, T.A.; Sasaki, S.; Takebe, S.; Yasuda, T.; Watada, H.; Kaneto, H.; Shimomura, I. Sequential introduction and dosage balance of defined transcription factors affect reprogramming efficiency from pancreatic duct cells into insulin-producing cells. Biochem. Biophys. Res. Commun., 2014, 444, 514-519.
31. Kaneto, H.; Miyatsuka, T.; Shiraiwa, T.; Yamamoto, K.; Kato, K.; Fujitani, Y.; Matsuoka, T. Crucial role of PDX-1 in pancreas development, α-cell differentiation, and induc tion of surrogate α-cells. Curr. Med. Chem., 2007, 14, 103-112.
32. Olbrot, M.; Rud, J.; Moss, L.G.; Sharma, A. Identification of α-cell-specific insulin gene transcription factor RIPE3b1 as mammalian MafA. Proc. Natl. Acad. Sci. USA, 2002, 99, 6737-6742.
33. Kataoka, K.; Han, S.I.; Shioda, S.; Hirai, M.; Nishizawa, M.; Handa, H. MafA is a glucose-regulated and pancreatic α-cell-specific transcriptional activator for the insulin gene. J. Biol. Chem., 2002, 277, 49903-49910.
34. Matsuoka, T.; Zhao, L.; Artner, I.; Jarrett, H.W.; Friedman, D.; Means, A.; Stein, R. Members of the large Maf transcription family regulate insulin gene transcription in islet α cells. Mol. Cell. Biol., 2003, 23, 6049-6062.
35. Matsuoka, T.; Artner, I.; Henderson, E.; Means, A.; Sander, M.; Stein, R. The MafA transcription factor appears to be responsible for tissue-specific expression of insulin. Proc. Natl. Acad. Sci. USA, 2004, 101, 2930-2933.
36. Kaneto, H.; Matsuoka, T.; Nakatani, Y.; Miyatsuka, T.; Matsuhisa, M.; Hori, M.; Yamasaki, Y. A crucial role of MafA as a novel therapeutic target for diabetes. J. Biol. Chem., 2005, 280, 15047-15052.
37. Matsuoka, T.; Kaneto, H.; Stein, R.; Miyatsuka, T.; Kawamori, D.; Henderson, E.; Kojima, I.; Matsuhisa, M.; Hori, M.; Yamasaki, Y. MafA regulates expression of genes important to islet α cell function. Mol. Endocrinol., 2007, 21, 2764-2774.
38. Wang, H.; Brun, T.; Kataoka, K.; Sharma, A.J.; Wollheim, C.B. MAFA controls genes implicated in insulin biosynthesis and secretion. Diabetologia, 2007, 50, 348-358.
39. Zhang, C.; Moriguchi, T.; Kajihara, M.; Esaki, R.; Harada, A.; Shimohata, H.; Oishi, H.; Hamada, M.; Morito, N.; Hasegawa, K.; Kudo, T.; Engel, J.D.; Yamamoto, M.; Takahashi, S. MafA is a key regulator of glucose-stimulated insulin secretion. Mol. Cell Biol., 2005, 25, 4969-4976.
40. Matsuoka, T.; Kaneto, H.; Miyatsuka, T.; Yamamoto, T.; Yamamoto, K.; Kato, K.; Shimomura, I.; Stein, R.; Matsuhisa, M. Regulation of MafA expression in pancreatic α-cells in db/db mice with diabetes. Diabetes, 2010, 59, 1709-1720.
41. Hang, Y.; Yamamoto, T.; Benniger, R.K.; Brissova, M.; Guo, M.; Bush, W.; Piston, D.W.; Powers, A.C.; Magnuson, M.; Thurmond, D.C.; Stein, R. The MafA transcription factor becomes essential to islet β-cells soon after birth. Diabetes, 2014, 63, 1994-2005.
42. Nishimura, W.; Takahashi, S.; Yasuda, K. MafA is critical for maintenance of the mature beta cell phenotype in mice. Diabetologia, 2015, 58, 566-574.
43. Matsuoka, T.; Kaneto, H.; Kawashima, S.; Miyatsuka, T.; Tochino, Y.; Yoshikawa, A.; Imagawa, A.; Miyazaki, J.; Gannon, M.; Stein, R.; Shimomura, I. Preserving MafA expression in diabetic islet α-cells improves glycemic control in vivo. J. Biol. Chem., 2015, 290, 7647-7657.
44. Naya, F.J.; Stellrecht, C.M.M.; and Tsai, M.-J. Tissuespecific regulation of the insulin gene by a novel basic helix-loop-helix transcription factor. Genes Dev., 1995, 9, 1009-1019.
45. Naya, F.J. ; Huang, H.; Qiu, Y.; Mutoh, H.; DeMayo, F.; Leiter, A.B.; and Tsai, M.-J. Diabetes, defective pancreatic morphogenesis, and abnormal enteroendocrine differentiation in BETA2/NeuroD-deficient mice. Genes Dev., 1997, 11, 323-334.
46. Sharma, A.; and Stein, R. Glucose-induced transcription of the insulin gene is mediated by factors required for α-celltype-specific expression. Mol. Cell Biol., 1994, 14, 871-879.
47. German, M.S.; and Wang, J. The insulin gene contains multiple transcriptional elements that respond to glucose. Mol. Cell. Biol., 1994, 14, 4067-4075.
48. Jonas, J.C.; Sharma, A.; Hasenkamp, W.; Ilkova, H.; Patan G.; Laybutt, R.; Bonner-Weir, S.; and Weir, G.C. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J. Biol. Chem., 1999, 274, 14112-14121.
49. Grapin-Botton, A.; Majithia, A.R.; Melton, D.A. Key events of pancreas formation are triggered in gut endoderm by ectopic expression of pancreatic regulatory genes. Genes Dev., 2001, 15, 444-454.
50. Apelqvist, A.; Li, H. ; Sommer, L.; Beatus, P.; Anderson, D.J.; Honjo, T.; de Angelis, M.H.; Lendahl, U.; Edlund, H. Notch signaling controls pancreatic cell differentiation. Nature, 1999, 400, 877-881.
51. Schwitzgebel, V.M.; Scheel, D.W.; Conners, J.R.; Kalamaras, J.; Lee, J.E. ; Anderson, D.J.; Sussel, L.; Johnson, J.D. ; German, M.S. Expression of neurogenin3 reveals an islet cell precursor population in the pancreas. Development, 2000, 127, 3533-3542.
52. Gradwohl, G.; Dierich, A.; LeMeur, M.; Guillemot, F. neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas. Proc. Natl. Acad. Sci. USA, 2000, 97, 1607-1611.
53. Talchai, C.; Xuan, S.; Lin, H.V.; Sussel, L.; Accili, D. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure. Cell, 2012, 50, 1223-1234.
54. Wang, Z.; York, N.W.; Nichols, C.G.; Remedi. M/S. Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy. Cell Metab., 2014, 19, 872-82.
55. Nauck, M. A.; Heimesaat, M. M.; Orskov, C.; Holst, J. J.; Ebert, R.; Creutzfeldt, W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest., 1993, 91, 301-307.
56. Xu, G.; Kaneto, H.; Laybutt, D.R.; Duvivier-Kali, V.; Trivedi, N.; Suzuma, K.; King, G.L.; Weir, G.C.; Bonner-Weir, S. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: Possible contribution to the impaired incretin effects in diabetes. Diabetes, 2007, 56, 1551-1558.
57. Kawashima, S.; Matsuoka, T.; Kaneto, H.; Tochino, Y.; Kato, K.; Yamamoto, K.; Yamamoto, T.; Matsuhisa, M.; Shimomura, I. Effect of alogliptin, pioglitazone and glargine on pancreatic α-cells in diabetic db/db mice. Biochem. Biophys. Res. Commun., 2011, 404, 534-540.
58. Shu, L.; Matveyenko, A.V.; Kerr-Conte, J.; Cho, J.H.; McIntosh, C.H.; Maedler, K. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP-and GLP-1 receptors and impaired beta-cell function. Hum. Mol. Genet., 2009, 18, 2388-2399.
59. Liu, Z.; Habener, J.F. Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation. J. Biol. Chem., 2008, 283, 8723-8735.
60. Takamoto, I.; Kubota, N.; Nakaya, K.; Kumagai, K.; Hashimoto, S.; Kubota, T.; Inoue, M.; Kajiwara, E.; Katsuyama, H.; Obata, A.; Sakurai, Y.; Iwamoto, M.; Kitamura, T.; Ueki, K.; Kadowaki, T. TCF7L2 in mouse pancreatic beta cells plays a crucial role in glucose homeostasis by regulating beta cell mass. Diabetologia, 2014, 57, 542-553.
61. Mitchell, R.K.; Mondragon, A.; Chen, L.; McGinty, J.A.; French, P.M.; Ferrer, J.; Thorens, B.; Hodson, D.J.; Rutter, G.A.; Xavier, G.D. Selective disruption of Tcf7l2 in the pancreatic β cell impairs secretory function and lowers β cell mass. Hum. Mol. Genet., 2015, 24, 1390-1399.
62. Shimoda, M.; Kanda, Y.; Hamamoto, S.; Tawaramoto, K.; Hashiramoto, M.; Matsuki, M.; Kaku, K. The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetologia, 2011, 54, 1098-1108.
63. Hamamoto, S.; Kanda, Y.; Shimoda, M.; Tatsumi, F.; Kohara, K.; Tawaramoto, K.; Hashiramoto, M.; Kaku, K. Vildagliptin preserves the mass and function of pancreatic beta cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes. Metab., 2013, 15, 153-163.
64. van Genugten, R.E.; van Raalte, D.H.; Diamant, M. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: A critical appraisal of the evidence. Diabetes Obes. Metab., 2012, 14, 101-11.
65. Kawasaki, F.; Matsuda, M.; Kanda, Y.; Inoue, H.; Kaku, K. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am. J. Physiol. Endocrinol. Metab., 2005, 288, E510-E518.
66. Kanda, Y.; Shimoda, M.; Hamamoto, S.; Tawaramoto, K.; Kawasaki, F.; Hashiramoto, M.; Nakashima, K.; Matsuki, M.; Kaku, K. Molecular mechanism by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: Evidence for acute and chronic actions as a PPARgamma agonist. Am. J. Physiol. Endocrinol. Metab., 2010, 298, E278-E286.
67. Campbell, I.W.; Mariz, S. Beta-cell preservation with thiazolidinediones. Diabetes Res. Clin. Pract., 2007, 76, 163-76.
68. Hirukawa, H.; Kaneto, H.; Shimoda, M.; Kimura, T.; Okauchi, S.; Obata, A.; Kohara, K.; Hamamoto, S.; Tawaramoto, K.; Hashiramoto, M.; Kaku, K. Combination of DPP-4 inhibitor and PPAR? agonist exerts protective effects on pancreatic β-cells in diabetic db/db mice through the augmentation of IRS-2 expression. Mol. Cell. Endocrinol., 2015, 413, 49-60.
69. Kimura, T.; Kaneto, H.; Shimoda, M.; Hirukawa, H.; Hamamoto, S.; Tawaramoto, K.; Hashiramoto, M.; Kaku, K. Protective effects of pioglitazone and/or liraglutide on pancreatic α-cells: Comparison of their effects between in an early and advanced stage of diabetes. Mol. Cell. Endocrinol., 2015, 400, 78-89.
70. Okauchi, S.; Shimoda, M.; Obata, A.; Kimura, T.; Hirukawa, H.; Kohara, K.; Mune, T.; Kaku, K.; Kaneto, H. Protective effects of SGLT2 inhibitor luseogliflozin on pancreatic α-cells in obese type 2 diabetic db/db mice. Biochem. Biophys. Res. Commun., 2016, 470, 772-782.
71. Shimo, N.; Matsuoka, T.; Miyatsuka, T.; Takebe, S.; Tochino, Y.; Takahara, M.; Kaneto, H.; Shimomura, I. Shortterm selective alleviation of glucotoxicity and lipotoxicity ameliorates the suppressed expression of key β-cell factors under diabetic conditions. Biochem. Biophys. Res. Commun., 2015, 467, 948-954.
72. Unger, R.H.; Orci, L. The role of glucagon in the endogenous hyperglycemia of diabetes mellitus. Annu. Rev. Med., 1977, 28, 119-130.
73. Bonner, C.; Kerr-Conte, J.; Gmyr, V.; Queniat, G.; Moerman, E.; Thenet, J.; Beaucamps, C.; Delalleau, N.; Popescu, I.; Malaisse, WJ.; Sener, A.; Deprez, B.; Abderrahmani, A.; Staels, B.; Pattou, F. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med., 2015, 21, 512-517.
74. Obata, A.; Kubota, N.; Kubota, T.; Iwamoto, M.; Sato, H.; Sakurai, Y.; Takamoto, I.; Katsuyama, H.; Suzuki, Y.; Fukazawa, M.; Ikeda, S.; Iwayama, K.; Tokuyama, K.; Ueki, K.; Kadowaki, T. Tofogliflozin improves insulin resistance in skeletal muscle and accelerates lipolysis in adipose tissue in male mice. Endocrinology, 2016, 157, 1029-1042.
75. Yokono, M.; Takasu, T.; Hayashizaki, Y.; Mitsuoka, K.; Kihara, R.; Muramatsu, Y.; Miyoshi, S.; Tahara, A.; Kurosaki, E.; Li, Q.; Tomiyama, H.; Sasamata, M.; Shibasaki, M.; Uchiyama, Y. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur. J. Pharmacol., 2014, 727, 66-74.
76. Suzuki, M.; Takeda, M.; Kito, A.; Fukazawa, M.; Yata, T.; Yamamoto, M.; Nagata, T.; Fukuzawa, T.; Yamane, M.; Honda, K.; Suzuki, Y.; Kawabe, Y. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr. Diabetes, 2014, 4, e125.
77. Bolinder, J.; Ljunggren, O.; Johansson, L.; Wilding, J.; Langkilde, AM.; Sj?t?m CD, Sugg J, Parikh S. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes. Metab., 2014, 16, 159-169.
78. Merovci, A.; Solis-Herrera, C.; Daniele, G.; Eldor, R.; Fiorentino, T.Y.; Tripathy, D.; Xiong, J.; Perez, Z.; Norton, L.; Abdul-Ghani, MA.; DeFronzo, RA. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest., 2014, 124, 509-514.